Results 41 to 50 of about 83,436 (250)

The anticancer peptide RT53 induces immunogenic cell death. [PDF]

PLoS ONE, 2018
In recent years, immunogenic cell death (ICD) has emerged as a revolutionary concept in the development of novel anticancer therapies. This particular form of cell death is able, through the spatiotemporally defined emission of danger signals by the ...
Ewa Pasquereau-Kotula, Justine Habault, Guido Kroemer, Jean-Luc Poyet   +3 more
doaj   +1 more source

The Concept of Immunogenic Cell Death in Antitumor Immunity [PDF]

Klinicka onkologie, 2015
Cancer cell death can be immunogenic or nonimmunogenic depending on the initiating stimulus. The immunogenic characteristics of immunogenic cell death are mainly mediated by damage-associated molecular patterns represented by preapoptotic exposure of calreticulin and heat shock proteins (HSP70 and HSP90) from endoplasmic reticulum at the cell surface ...
J, Fučíková, J, Bartůňková, R, Špíšek   +2 more
openaire   +2 more sources

Trial watch: chemotherapy-induced immunogenic cell death in oncology

OncoImmunology, 2023
Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell death that activates, rather than suppresses, innate and adaptive immune responses. Such responses culminate into T cell-driven immunity against antigens derived
Jenny Sprooten, Raquel S. Laureano, Isaure Vanmeerbeek, Jannes Govaerts, Stefan Naulaerts, Daniel M. Borras, Lisa Kinget, Jitka Fucíková, Radek Špíšek, Lenka Palová Jelínková, Oliver Kepp, Guido Kroemer, Dmitri V. Krysko, An Coosemans, Rianne D.W. Vaes, Dirk De Ruysscher, Steven De Vleeschouwer, Els Wauters, Evelien Smits, Sabine Tejpar, Benoit Beuselinck, Sigrid Hatse, Hans Wildiers, Paul M. Clement, Peter Vandenabeele, Laurence Zitvogel, Abhishek D. Garg   +26 more
doaj   +1 more source

Mathematical Models of Death Signaling Networks

Entropy, 2022
This review provides an overview of the progress made by computational and systems biologists in characterizing different cell death regulatory mechanisms that constitute the cell death network.
Madhumita Srinivasan, Robert Clarke, Pavel Kraikivski   +2 more
doaj   +1 more source

Viral strategies for the evasion of immunogenic cell death [PDF]

Journal of Internal Medicine, 2010
Abstract.  Galluzzi L, Kepp O, Morselli E, Vitale I, Senovilla L, Pinti M, Zitvogel L, Kroemer G (INSERM, U848; Institut Gustave Roussy; and Université Paris Sud‐XI, Paris, France; Università degli studi di Modena e Reggio Emilia, Modena, Italy; INSERM, U805, Paris, France). Viral strategies for the evasion of immunogenic cell death (Symposium).
GALLUZZI, Lorenzo, Kepp O, MORSELLI, EUGENIA, Vitale I, Senovilla L, PINTI, Marcello, Zitvogel L, Kroemer G.   +7 more
openaire   +3 more sources

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Screening for immunogenic cell death [PDF]

Science-Business eXchange, 2012
French researchers have used a fluorescence-based screening platform to identify small molecules that induced immunogenic cell death in mouse tumors. Next, the group plans to test the best hits in a Phase I/II trial to treat locally invasive head and neck cancers in combination with chemotherapy.
openaire   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Immunogenic Cell Death Role in Urothelial Cancer Therapy

Current Oncology, 2022
Purpose: Bladder cancer is the 13th most common cause of cancer death with the highest lifetime cost for treatment of all cancers. This scoping review clarifies the available evidence on the role of a novel therapeutic approach called immunogenic cell ...
Reza Yadollahvandmiandoab, Mehrsa Jalalizadeh, Keini Buosi, Herney Andrés Garcia-Perdomo, Leonardo Oliveira Reis   +4 more
doaj   +1 more source

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

Molecular Oncology, EarlyView.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski, Júlia Perera‐Bel, Alejo Rodriguez‐Vida, Nuria Juanpere, Jihyun Lee, Daniel E. Michaud, Jennifer L. Guerriero, Kent W. Mouw, Aristotelis Bamias, Filipe L. F. Carvalho, Joaquim Bellmunt   +10 more
wiley   +1 more source